Monopar Therapeutics Inc. (NASDAQ: MNPR) announced that Hepatology Communications published results from a Phase 2 study of ALXN1840 (tiomolibdate choline) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE